Demand for Meningococcal Vaccine and Impact of COVID-19……..Posted by Mrudula Anil Karmarkar on January 17th, 2022 The global meningococcal vaccine market size is expected to reach USD 5.9 billion by 2027, expanding at a CAGR of 9.5%, according to a new report by Grand View Research, Inc. Increasing prevalence of meningitis is one of the major factors attributed to the market growth. Furthermore, according to the European Centre for Disease Prevention and Control (ECDC), it was estimated that in 2017, 3,221 confirmed cases were observed in the EU member states, in which 58% of cases were found in the U.K., France, Spain, and Germany. In addition, manufacturers are receiving Break Through Designation (BTD) for the development of improved vaccines as compared to available therapy. For instance, in February 2018, GlaxoSmithKline plc received BTD for Bexsero for extending its use in the age group below 11 years. Such initiatives are expected to improve meningococcal prevention, which in turn is anticipated to drive the market. Initiatives undertaken by the government to combat the rising incidence of the disease is anticipated to boost the market growth. For instance, from April 2020, Nimenrix was made available for free as a part of the National Immunisation Program (NIP) for the age group 14 to 16 years. Nimenrix is a single dose quadrivalent meningococcal vaccine that targets serogroups A, C, W & Y. In addition, rising awareness programs focused on prevention of the target disease is expected to fuel market growth. For instance, in April 2020, the National Day of Action against Meningitis B was launched by the Meningitis B Action Project on World Meningitis Day to improve awareness of meningitis regarding available vaccines such as MenACWY and MenB among healthcare professional, students, and parents. Furthermore, the government provision of free vaccination to reduce the spread of the target disease is anticipated to boost the market growth. For instance, in November 2018, the government of New Zealand started a free vaccination program in Northland for infants and children. To Request Sample Copy of this report, click the link: https://www.grandviewresearch.com/industry-analysis/meningococcal-vaccines-market/request/rs1 The availability of vaccines at lower prices in countries with an increasing prevalence of meningococcal diseases is anticipated to fuel the revenue of the manufacturers and drive the market. For instance, under the Meningitis Vaccine Project, MenAfriVac costs less than USD 0.5 per dose. Meningococcal Vaccine Market Report Highlights
The increasing prevalence of meningitis is one of the major factors expected to drive the market. According to the Centers for Disease Control and Prevention (CDC), around 1.2 million cases of bacterial meningitis are projected to occur globally every year. Increasing initiatives by government and regulatory authorities to combat the rising prevalence of meningitis is expected to boost the market growth. For instance, in May 2018, “Defeating meningitis by 2030” was introduced at the World Health Assembly by Eastern Mediterranean and African regions to develop a strategic roadmap for meningitis prevention by prioritizing areas for research and enhanced control activities. The presence of a strong pipeline of meningococcal vaccines is expected to maintain a significant market share of the key players. For instance, Pfizer has developed a new molecular entity named PF-06886992 for Serogroups ABCWY Meningococcal Infections which is currently in Phase II clinical trials. Some of the prominent players in the meningococcal vaccine market include:
About Grand View Research Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare. Like it? Share it!More by this author |